Anixa Biosciences Inc. logo

Anixa Biosciences Inc. (ANIX)

Market Closed
20 Jun, 20:00
NASDAQ (CM) NASDAQ (CM)
$
3. 38
-0.17
-4.79%
$
114.35M Market Cap
- P/E Ratio
0% Div Yield
244,186 Volume
-0.37 Eps
$ 3.55
Previous Close
Day Range
3.31 3.6
Year Range
2.07 4.2

Summary

ANIX closed today lower at $3.38, a decrease of 4.79% from yesterday's close, completing a monthly increase of 20.71% or $0.58. Over the past 12 months, ANIX stock gained 42.02%.
ANIX is not paying dividends to its shareholders.
The last earnings report, released on Jun 06, 2025, exceeded the consensus estimates by 0.01%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Anixa Biosciences Inc. has completed 6 stock splits, with the recent split occurring on Oct 18, 2016.
The company's stock is traded on 6 different exchanges and in various currencies, with the primary listing on NASDAQ (CM) (USD).
Want to track ANIX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

ANIX Chart

Chart

Empty chart
The chart has 2 Y axes displaying values, and values.
Loading, please wait...
End of interactive chart.
Anixa Biosciences to Host an Investor Webcast on June 26, 2025

Anixa Biosciences to Host an Investor Webcast on June 26, 2025

SAN JOSE, Calif. , June 20, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it will host an investor webcast presentation on June 26, 2025 at 2:00 PM EDT.

Prnewswire | 20 hours ago
What Makes ANIXA BIOSCIENCES INC (ANIX) a Strong Momentum Stock: Buy Now?

What Makes ANIXA BIOSCIENCES INC (ANIX) a Strong Momentum Stock: Buy Now?

Does ANIXA BIOSCIENCES INC (ANIX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks | 1 week ago
Anixa Biosciences' Breast Cancer Vaccine Receives National News Coverage

Anixa Biosciences' Breast Cancer Vaccine Receives National News Coverage

SAN JOSE, Calif. , June 10, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its CEO, Dr. Amit Kumar, was interviewed by the New York Post to discuss Anixa's breast cancer vaccine, and the breast cancer vaccine was featured on Fox News' "Fox & Friends.

Prnewswire | 1 week ago

Anixa Biosciences Inc. Dividends

ANIX is not paying dividends to its shareholders.

Anixa Biosciences Inc. Earnings

6 Jun 2025 Date
-
Cons. EPS
-
EPS
21 Mar 2025 Date
-
Cons. EPS
-
EPS
6 Sep 2024 Date
-
Cons. EPS
-
EPS
4 Jun 2024 Date
-
Cons. EPS
-
EPS
9 May 2024 Date
-
Cons. EPS
-
EPS
ANIX is not paying dividends to its shareholders.
6 Jun 2025 Date
-
Cons. EPS
-
EPS
21 Mar 2025 Date
-
Cons. EPS
-
EPS
6 Sep 2024 Date
-
Cons. EPS
-
EPS
4 Jun 2024 Date
-
Cons. EPS
-
EPS
9 May 2024 Date
-
Cons. EPS
-
EPS

Anixa Biosciences Inc. (ANIX) FAQ

What is the stock price today?

The current price is $3.38.

On which exchange is it traded?

Anixa Biosciences Inc. is listed on NASDAQ (CM).

What is its stock symbol?

The ticker symbol is ANIX.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 114.35M.

Has Anixa Biosciences Inc. ever had a stock split?

Anixa Biosciences Inc. had 6 splits and the recent split was on Oct 18, 2016.

Anixa Biosciences Inc. Profile

Biotechnology Industry
Healthcare Sector
Dr. Amit Kumar Ph.D. CEO
NASDAQ (CM) Exchange
03528H109 Cusip
US Country
5 Employees
- Last Dividend
26 Jun 2015 Last Split
1 Jan 1987 IPO Date

Overview

Anixa Biosciences, Inc. is a pioneering biotechnology enterprise committed to the innovation of novel treatments and vaccines addressing the urgent needs within oncology and infectious diseases sectors. Since its inception in 1982 and formerly known as ITUS Corporation before rebranding in October 2018, Anixa has been at the forefront of developing groundbreaking therapies. Headquartered in San Jose, California, the company concentrates on leveraging advancements in science and technology to create solutions for diseases with significant unmet medical needs, particularly focusing on various forms of cancer.

Products and Services

  • Chimeric Endocrine Receptor T-Cell Therapy

    This novel form of chimeric antigen receptor T-cell (CAR-T) technology is under development by Anixa Biosciences with a primary focus on treating ovarian cancer. By tailoring the body's own immune cells to better recognize and fight cancer, this therapy represents a promising advance in personalized medicine for ovarian cancer patients.

  • Vaccine Against Triple Negative Breast Cancer

    An innovative project undertaken by Anixa is the development of a vaccine aimed at combating triple negative breast cancer. This form of breast cancer is particularly challenging to treat due to the lack of hormone receptors, which are typically targeted in other breast cancer treatments. Anixa's vaccine seeks to stimulate the immune system to prevent or treat this aggressive type of cancer.

  • Preventative Vaccine Against Ovarian Cancer

    Focusing on prevention, Anixa is also working on a vaccine aimed at ovarian cancer, one of the most deadly forms of gynecological cancer. The goal of this vaccine is to train the immune system to recognize and eliminate cells that could potentially develop into cancer, thus offering a prophylactic solution to high-risk individuals.

  • Immuno-Therapy Drugs Against Cancer

    Aside from vaccines and targeted cell therapies, Anixa Biosciences is also developing a range of immuno-therapy drugs designed to empower the immune system in fighting against cancer. These drugs work by various mechanisms to enhance the body's natural defense systems, showing promise in treating different types of cancer.

Contact Information

Address: 3150 Almaden Expressway
Phone: 408 708 9808